Brief: Supriya Lifescience Says US FDA Inspects Supriya Lifescience Lote Facility
22/04/2026 07:20
April 22 (Reuters) - Supriya Lifescience Ltd SPRL.NS: US FDA INSPECTS SUPRIYA LIFESCIENCE LOTE FACILITY FROM FEB 2 TO FEB 6, 2026 US FDA ISSUES FORM 483 WITH ONE MINOR OBSERVATION TO SUPRIYA LIFESCIENCE RECEIVES EIR INDICATING VOLUNTARY ACTION INDICATED (VAI) Source text: ID:nNSEbX2QY0 Further company coverage: SPRL.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Supriya Lifescience
See all newsBrief: Supriya Lifescience Says Court Orders Provisional Release Of 200 KG Ketamine Hydrochloride Consignment
Brief: Supriya Lifescience Limited Says June-Quarter Profit 240.4 Million Rupees
India's Supriya Lifescience on track for worst fall in a month on probe into official
Brief: Supriya Lifescience Says Lote Facility Receives USFDA EIR With Voluntary Action Indicated Classification
India's Supriya Lifescience rises on higher quarterly profit